Navigation Links
Moderna Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
Date:1/6/2014

CAMBRIDGE, Mass., Jan. 6, 2014 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that President and founding Chief Executive Officer Stephane Bancel will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference.

Bancel will focus on the potential of Moderna's mRNA therapeutics to transform drug development across a wide range of diseases and improve patients' lives.

The presentation will take place on Tuesday, January 14 at 8:30 a.m. PT in Elizabethan C/D at the Westin St. Francis Hotel in San Francisco.

For more information on Moderna Therapeutics please visit www.modernatx.com.

About Moderna Therapeutics                                                                                 

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 250 patent applications with more than 12,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.

For information contact:
Maria Favorito
Feinstein Kean Healthcare
617-761-6720
maria.favorito@fkhealth.com


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Visiomed, the French ... since 1997, is changing the landscape of healthcare ... patients with pro-active, custom-made solutions. Recognizing the rising ... and affordable healthcare without walls, Visiomed has launched ... developed with healthcare professionals that is empowering the ...
(Date:2/23/2017)... YORK , Feb. 23, 2017  Genesis Healthcare ... Company. The announcement was made by Bill Monast ... David Hartley and Nathan Feltman , executives ... Genesis Healthcare Services, LLC. This acquisition ... largest provider of technology enabled durable medical equipment (DME) ...
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: ... markets innovative proprietary products for the urology market, will ... year ended December 31, 2016 before the market open ... Company will host a conference call and webcast to ... March 9, 2017 at 11:00 a.m. Eastern Time (10:00 ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz ... a new Indiegogo campaign . Individuals are now able to contribute to the ... area, either as a participating patient or through an Indiegogo donation. The entirety of ...
(Date:2/23/2017)... ... , ... HealthPostures, the desk for standing designer headquartered in Prior Lake, Minnesota ... Minneapolis Home and Garden Show which is being held February 24 through 26 and ... the Minneapolis Convention Center. , From its broad line of sit stand desk ...
(Date:2/23/2017)... Va. (PRWEB) , ... February 23, 2017 , ... ... or problems. He has also continued to spiritually evolve, which is the purpose of ... book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers ...
(Date:2/22/2017)... ... 22, 2017 , ... Our high-octane society demands higher stands ... brain. , Power On, a mental performance enhancer from Modus Nutrition, provides scientifically ... capsule contains Cognizin® Citicoline, a branded form of the brain health nutrient citicoline ...
(Date:2/22/2017)... Tampa, Fla. (PRWEB) , ... February 22, 2017 ... ... the field of regenerative medicine in recent years. The technology is so cutting ... sanction regulations on the protocol for stem cell procedures. However, successful patient outcomes ...
Breaking Medicine News(10 mins):